Abstract: A display device includes a substrate including a display area and a driving circuit area, a first insulating layer, a second insulating layer on the first insulating layer, a first transistor in the display area, and including a first semiconductor pattern layer formed as a semiconductor layer on the second insulating layer, a first gate electrode on the first semiconductor pattern layer, and a first lower electrode overlapping the first semiconductor pattern layer, and a second transistor in the driving circuit area, and including a second semiconductor pattern layer formed as the semiconductor layer, a second gate electrode on the second semiconductor pattern layer, and a second lower electrode overlapping the second semiconductor pattern layer, wherein the first lower electrode is between the substrate and the first insulating layer, and the second lower electrode is between the first insulating layer and the second insulating layer.

Abstract: A light-emitting element includes a light-emitting element core extending in a direction and including a first semiconductor layer, a second semiconductor layer disposed on the first semiconductor layer, and a device active layer disposed between the first semiconductor layer and the second semiconductor layer, a device insulating film surrounding a lateral surface of the light-emitting element core, and a reflective film disposed on an outer lateral surface of the device insulating film and surrounding at least a lateral surface of the device active layer.

Abstract: The present invention relates to a composition for proliferating natural killer cells, comprising feeder cells and a method for proliferating natural killer cells. Specifically, the present invention relates to a method for proliferating natural killer cells by using feeder cells that are transformed to express at least one gene selected from the group consisting of B7H6, CD137L, IL-15, and IL-15R?.

Abstract: Disclosed is an anticancer composition, comprising an inhibitor against WIG1 and/or YPEL5 or against a protein encoded by the gene. A composition for screening an anticancer agent comprising a nucleic acid having a sequence complementary to an mRNA of WIG1 and/or YPEL5, or an antibody to a protein encoded by the gene is also provided. Also, a method is provided for screening an anticancer agent, which comprises: (A) quantitatively analyzing expression of WIG1 and/or YPEL5 at an mRNA or protein level in a tumor cell which is not treated with a candidate for an anticancer agent; (B) quantitatively analyzing expression of the gene at an mRNA or protein level in a tumor cell after treatment of the candidate for an anticancer agent; and (C) selecting the candidate if the expression level of the gene is increased in step (B), compared to step (A).

Abstract: Disclosed is an anticancer composition, comprising an inhibitor against WIG1 and/or YPEL5 or against a protein encoded by the gene. A composition for screening an anticancer agent comprising a nucleic acid having a sequence complementary to an mRNA of WIG1 and/or YPEL5, or an antibody to a protein encoded by the gene is also provided. Also, a method is provided for screening an anticancer agent, which comprises: (A) quantitatively analyzing expression of WIG1 and/or YPEL5 at an mRNA or protein level in a tumor cell which is not treated with a candidate for an anticancer agent; (B) quantitatively analyzing expression of the gene at an mRNA or protein level in a tumor cell after treatment of the candidate for an anticancer agent; and (C) selecting the candidate if the expression level of the gene is increased in step (B), compared to step (A).